Hoffmann-la Roche Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Roche Diagnostics Operations, Inc.

The United States of America As Represented by the Department of Health

Jarema Peter Kochan

Jean Pierre Kinet

Johann Karl

Michael Tacke

Wolfgang Rollinger

Markus Roessler

Yu-Ching Eugene Pan

Kuo-Sen Huang

Shirley H Li

Bernard J Scallon

Thomas C Tsang

Charles Roger Burghardt

Stephen Dalton

Erik Roy Rasmussen

Mark A Osborne

The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP/seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

Method for providing diagnosis of cancer using seprase as a marker

The invention pertains to methods for measuring different forms of human adiponectin that are present in human plasma/serum, and more specifically methods are based on an ELISA assay that utilizes different monoclonal antibodies directed against adiponectin, in combination with different polyclonal antibodies directed against different domains of human adiponectin. The invention also provides unique isoforms of adiponectin and antibodies thereto, including polyclonal and monoclonal antibodies.

Characterization and identification of unique human adiponectin isoforms and antibodies

A Polypeptide and DNA Sequence corresponding to the human receptor high affinity receptor for IgE as well as replicable microbial expression vehicles, transformed microorganisms, and cultures of microbial cells which produce this polypeptide.

Polypeptide and DNA sequence corresponding to human receptor with high affinity for IgE

Polypeptide and DNA sequence corresponding to the human receptor with

Methods are provided for studying protein-protein interactions which require posttranslational modification of one of the proteins. The interaction is detected by reconstituting the activity of a transcriptional activator. This activity is dependent on the interactions between three different proteins. These include two chimeric proteins, one of which must be posttranslationally modified by the activity of the third protein in order for the chimeric proteins to interact. One of the chimeric proteins contains a transcriptional activation domain fused to a test protein. The second chimeric protein contains a DNA-binding domain of a transcriptional activator fused to the other test protein.

Method to detect protein-protein interactions

The present invention involves the protein glycosyl-phosphatidyl-specific phospholipase D (GPI-PLD) in a substantially pure form, an isolated nucleotide sequence encoding GPI-PLD, vectors containing the isolated nucleotide sequence encoding GPI-PLD, and cells transformed by a vector containing the isolated nucleotide sequence encoding GPI-PLD, also nucleotide sequences, vectors and cells comprising hybrid genes with GPI-PLD, and methods for producing secreted proteins.

Glycosyl-phosphatidylinositol-specific phospholipase D

Growing community of inventors

Verona, NJ, United States of America

Jarema Peter Kochan